Neuros Medical, a Case Western Reserve University spinout, has raised $69.8m since it was founded in 2008.

The cancer immunothrapy developer has filed to raise up to $100m in an offering that will follow $211m from backers including Celgene and Bristol-Myers Squibb.

Boston Scientific-backed pain relief implant developer Neuros has now raised about $70m in total and is targeting $42.8m in its latest round.

Adagio has raised money in a GV-led series B round that will support the entry of its covid-19 drug candidate into clinical trials early next year.

Ysios Capital has supplied a series A extension that follows an initial tranche co-led by Kurma Partners and Sunstone Life Science Ventures in November 2020.

Julius-Maximilians-University of Würzburg's cancer immunotherapy developer Catalym plans to move its lead asset into the clinic next month.

Legend Capital was among the participants as Rec-Biotechnology raised series B funding that will be used for clinical trials of its vaccine candidates.

The genitourinary tumour drug developer's latest round follows a June series C-plus round featuring C&D, Tigermed and SAIC Capital.

3M Ventures and NTTVC joined new and existing investors to help the cardiopulmonary virtual care provider boost its overall funding to $92m.

Novartis Venture Fund took part in a series B round closed as Catalym prepares to move its lead cancer immunotherapy asset into the clinic next month.